Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with tocilizumab, has been identified. Systemic glucocorticosteroids use may be considered acceptable in such patients in life-threatening situations, wh...
Main Authors: | K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2020-10-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/520 |
Similar Items
-
Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01) -
Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020-10-01) -
Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
by: K. B. Mirzaev, et al.
Published: (2020-10-01) -
Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020-10-01) -
Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)